Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
It’s an interesting challenge, commercializing in Europe the first novel pharmaceuticals to be developed and launched by Merck KGaA in a decade. The new head of its EMEA region explains his approach to the task.
Latest From Companies
Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.
TiGenix CEO Eduardo Bravo outlines group's commercialization plans for CPF candidate Cx601 in Europe and the US.
There are no actual data yet but the news that the closely-watched IMpower 150 study met a goal of progression-free survival and showed 'encouraging' signs on the overall survival endpoint has made IO rivals sit up, especially Merck & Co.
Europe's regulators have followed their US counterparts and given the green light to GSK's Trelegy. Now the company is hoping that having the first once-daily single inhaler triple therapy for COPD will boost its respiratory business.
Emerging Company Profile: ImmuneOncia may be late entering the market for PD-L1 inhibitors, but the joint venture between Yuhan and Sorrento Therapeutics aims to develop best-in-class immuno-oncology drugs with differentiated products and strategy.
Asked by Scrip to name two big changes coming pharma's way, Merck KGAA Healthcare CEO Belén Garijo identified artificial intelligence and outcome-based pacts as 'ways of the future'.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.